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a  b  s  t  r  a  c  t
Heart  failure still  remains  one  of the  leading  causes  of morbidity  and  mortality  worldwide.  A major
contributing  factor  is  reactive  oxygen/nitrogen  species  (RONS)  overproduction  which  is associated  with
cardiac remodeling  partly  through  cardiomyocyte  apoptosis.  Peroxisome  proliferator-activated  receptors
(PPARs)  are  ligand-activated  transcription  factors  that  belong  to the  nuclear  receptor  superfamily  and
have  been  implicated  in  cardioprotection.  However,  the molecular  mechanisms  are  largely  unexplored.  In
this study  we  sought  to  investigate  the  potential  beneﬁcial  effects  evoked  by  activation  of  PPAR/  under
the  setting  of  oxidative  stress  induced  by  H2O2 in  adult  rat  cardiac  myocytes.  The  selective  PPAR/  ago-
nist  GW0742  inhibited  the  H2O2-induced  apoptosis  and  increased  cell  viability.  In  addition,  generation
of  RONS  was  attenuated  in  cardiac  myocytes  in the presence  of  PPAR/  agonist.  These effects were  abol-
ished  in the presence  of the PPAR/ antagonist  indicating  that the effect  was  through  PPAR/  receptor
activation.  Treatment  with  PPAR/  agonist  was  also associated  with  attenuation  of  caspase-3  and  PARP
cleavage,  upregulation  of anti-apoptotic  Bcl-2  and concomitant  downregulation  of  pro-apoptotic  Bax.
In addition,  activation  of PPAR/ inhibited  the  oxidative-stress-induced  MMP-2  and  MMP-9  mRNAhemical compounds studied in this article:
ydrogen peroxide (PubChem CID: 784)
W0742 (PubChem CID: 9934458)
SK0660 (PubChem CID: 46233311)
upregulation.  It is concluded  that  PPAR/  activation  exerts  a cytoprotective  effect  in  adult  rat  cardiac
myocytes  subjected  to oxidative  stress  via inhibition  of  oxidative  stress,  MMP  expression,  and  apopto-
sis.  Our  data suggest  that the novel  connection  between  PPAR  signaling  and MMP  down-regulation  in
cardiac  myocytes  might  represent  a new  target  for the  management  of  oxidative  stress-induced  cardiac
dysfunction.
© 2015  Elsevier  Ltd.  All  rights  reserved.. Introduction
Cardiovascular diseases still remain one of the leading causes
f mortality and morbidity worldwide. Over the past years, clinical
nd experimental studies have provided substantial evidence that
xidative stress, deﬁned as an imbalance between free radical pro-
uction and their detoxiﬁcation by antioxidants, is an important
ontributing factor in the pathogenesis of a variety of cardiovas-
ular diseases including ischemic heart disease and heart failure
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ttp://dx.doi.org/10.1016/j.phrs.2015.03.008
043-6618/© 2015 Elsevier Ltd. All rights reserved.[1,2]. Excessive generation of reactive oxygen/nitrogen species
(RONS) causes cellular dysfunction, protein and lipid peroxida-
tion, DNA damage, activation of matrix metalloproteinases (MMPs)
and can lead to irreversible cell damage and cell death. The con-
trol of myocyte loss through suppression of cell death pathways
represents a promising strategy to prevent cardiac diseases. Ter-
minally differentiated adult cardiac myocytes die primarily by
apoptosis or necrosis [3]. Mitochondrial damage, cytochrome c
release and activation of cysteine proteases caspase 9 and 3 have
been implicated in apoptotic pathways. The Bcl-2 family proteins,
which contain both pro-apoptotic and anti-apoptotic members,
have been recognized as important modulators of cardiac myocyte
apoptosis as in other cells [4,5]. Bcl-2 family proteins act at the
mitochondria either as heterodimers or as homodimers to regu-
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omplexes appears to determine the predisposition to apoptosis
6].
The zinc-dependent endopeptidases, matrix metalloproteinases
MMPs), which have been known for their ability to proteolyse
xtracellular matrix proteins, play an important role in tissue
emodeling associated with various physiological and pathological
rocesses including chronic heart failure [7]. It is now recognized
hat MMPs can also have non-matrix related intracellular protein
argets and can regulate diverse cellular functions contributing to
ardiac dysfunction, such as oxidative stress-induced cell death
8–10]. Thus, MMPs  are considered to be viable drug targets in the
herapy of cardiac pathologies.
Peroxisome proliferator activated receptors (PPARs) are ligand
ctivated transcription factors that belong to the superfamily of
uclear hormone receptors and include 3 members (, /, ) with
issue speciﬁc but overlapping expression patterns. Upon activation
y their natural or pharmaceutical speciﬁc ligands, PPARs regulate
he expression of genes mostly involved in lipid and carbohydrate
etabolism, energy production and inﬂammation [11]. It has been
lso shown that PPARs may  play a role in regulating transcriptional
xpression of antioxidants, such as Cu/Zn-superoxide dismutase
SOD1), manganese superoxide dismutase (SOD2), and catalase
12,13]. Furthermore, emerging evidence indicates that activation
f PPARs, in particular PPAR or PPAR, may  exert cardioprotec-
ive effects beyond their metabolic effects, decreasing infarction
fter I/R and preventing cardiac remodeling and failure [14–17].
owever, the mechanisms underlying these protective effects are
argely unexplored, and it is still a matter of debate whether car-
ioprotection is attributable to the modulation of cardiac energy
etabolism or to antioxidative and anti-inﬂammatory effects of
PARs [18,19]. Although PPAR/ is the predominant subtype in
he heart, it is the least studied member of the PPAR family. Car-
iac PPAR/ deletion in mice resulted in depressed bioenergetics,
ardiac hypertrophy, and congestive heart failure [20] while it has
een shown that PPAR/ is essential for the adult heart to maintain
itochondrial capacity and oxidative metabolism [21].
Given the emerging role of PPAR/ in regulating mitochondrial
iogenesis and metabolism, we hypothesized that PPAR/ acti-
ation may  ameliorate oxidative stress-induced cardiac myocyte
amage. We  used the highly selective and potent PPAR/ agonist
W0742 [22] and a speciﬁc PPAR/ antagonist, GSK0660 [23] as
harmacological tools to evaluate the effects of receptor activation
n H2O2-induced cardiac myocyte apoptosis and explore the con-
ributing mechanisms. We  demonstrate that PPAR/ activation in
ardiac myocytes leads to the inhibition of RONS generation, down-
egulation of MMP-2 and MMP-9 gene expression and prevents
poptosis.
. Materials and methods
.1. Animals
Male Wistar rats weighing between 250 and 300 g were used.
nimals received proper care in compliance with the “Guidelines
or the Care and Use of Laboratory Animals” published by US
ational Institutes of Health (NIH publication No 85-23, revised
996) and the “Principles of laboratory animal care” published
y the Greek Government (160/1991) based on EU regulations
86/609). All surgery was performed under sodium pentobarbital
nesthesia, and all efforts were made to minimize suffering..2. Isolation of adult rat cardiac myocytes and treatments
Ventricular myocytes were isolated by cardiac retrograde aor-
ic perfusion and collagenase treatment as described previouslysearch 95–96 (2015) 102–110 103
[24]. Cells were ﬁnally resuspended in incubation medium, in
which added Ca2+ was gradually increased to 1 mM.  Prepara-
tions were considered satisfactory only if the yield of rod-shaped
cells was more than 70%. Experiments were performed 30 min
after dissociation. Cardiac myocytes were either left untreated, or
they were pre-treated with the PPAR/ agonist GW0742 (50 nM)
(Sigma–Aldrich Chemie GmbH, Taufkirchen, Germany) for 10 min
before exposure to H2O2 (0.1 mM).  When the PPAR/ antago-
nist GSK0660 (0.5 M)  (Tocris Bioscience, Bristol, UK) was used,
it was  added 10 min  before the addition of the agonist GW0742.
The concentration of H2O2 to induce apoptosis was chosen accord-
ing to our previous studies [24–26]. The optimal concentration of
PPAR/ agonist and antagonist were chosen according to prelim-
inary experiments. Preliminary experiments also established that
the concentrations of the agonist and antagonist used did not affect
the viability of cardiac myocytes. The experimental protocols are
summarized in Fig. 1.
2.3. Determination of cell viability
Cell viability was  determined using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay which
assesses mitochondrial activity in living cells. Cardiac myocytes
(105/sample) were either left untreated or they were pretreated
with PPAR/ agonist and/or antagonist (10 min), followed by
exposure to H2O2 for 3 h. Tetrazolium bromide at a concentration
0.1 mg/ml  was  added 10 min  before the end of incubation. At the
end of incubation, 1 ml of ethanol was added for 10 min  to dissolve
formazan precipitate. Absorbance was measured at 570 nm using a
microplate autoreader. Cell viability was  calculated as percentage
of control OD. Negative controls were used to ensure that the
drugs used for the cell treatments did not interfere on their own
with the formation of formazan.
2.4. Measurement of lactate dehydrogenase (LDH)
LDH release into the cell culture medium was used as an
indicator of cell death. LDH activity was  determined by spectro-
photometric analysis measuring the decrease in absorbance at
340 nm resulting from the oxidation of NADH. At the end of treat-
ments, cell culture medium was collected and LDH activity was
measured after addition of NADH (0.17 mM)  and sodium pyruvate
(1 mM).  LDH activity was expressed as munits/mg after determi-
nation of protein content per sample by Bradford assay.
2.5. Evaluation of apoptosis
Apoptosis was  determined by staining cells with Annexin V-
FITC and propidium iodide for ﬂow cytometric analysis (Biolegend
Europe). Brieﬂy, after treatments, cells were washed twice with
cold phosphate-buffered saline and resuspended. The cells were
incubated with Annexin V-FITC and propidium iodide for 15 min
in the dark. The samples were then subjected to ﬂow cytomet-
ric analysis to detect the percentage of apoptotic (FITC-stained)
and necrotic (PI-stained) cells in a given population. Fluores-
cence was  measured on a CyFlow ML  ﬂow cytometer (Partec
GmbH, Germany). Preliminary experiments established that the
agonist GW0742 or the antagonist GSK0660 used for the treat-
ment of cells did not interfere on their own  in the measurement of
ﬂuorescence.
2.6. RONS detectionIntracellular RONS production was  evaluated using the 5-
(and-6)-chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate
(CM-H2DCFDA) (Sigma–Aldrich Chemie GmbH, Taufkirchen,
104 E. Barlaka et al. / Pharmacological Research 95–96 (2015) 102–110
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fig. 1. Diagram of experimental protocol for drug administration and induction of o
r  they were stimulated with H2O2 (0.1 mM). When used, PPAR/ agonist (GW, 50
as  used (GSK, 0.5 M),  it was  added 10 min  before the addition of PPAR/ agonis
ermany). In brief, cardiac myocytes were loaded with CM-
2DCFDA (5 g/ml) and then, they were either left untreated
r they were pretreated with the PPAR/ agonist GW0742 for
0 min  and/or the antagonist GSK0660 (0.5 M),  in the presence
r in the absence of H2O2 (0.1 mM)  for 3 h. RONS-induced ﬂuores-
ence was detected by ﬂow cytometry (CyFlow ML,  Partec GmbH,
ermany). Preliminary experiments established that GW0742 or
SK0660 did not interfere on their own in the measurement of
uorescence.
.7. Isolation of RNA and quantitative PCR (qPCR)
Total RNA was extracted using TRI Reagent (Molecular
esearch Center, Cincinnati, OH, USA) according to the manu-
acturer’s instructions. The RNA was resuspended in 0.1% (v/v)
iethylpyrocarbamate-treated water and its concentration was
etermined by absorbance at 260 nm.  The integrity of isolated
NA was veriﬁed on a 1% agarose gel. For cDNA synthesis, l g
f total RNA was denatured in the presence of random 9-mers
Takara, Japan) in a reaction volume of 10 l at 65 ◦C for 5 min.
NA was reverse-transcribed with PrimeScript Reverse Transcrip-
ase enzyme (Takara, Japan), dNTP’s (HyTest Ltd., Finland) and
uman Placental Ribonuclease inhibitor (HT Biotechnology Ltd.,
ambridge, UK). The reaction, in total volume of 20 l, was car-
ied out for 1 h at 37 ◦C, and was terminated by heat inactivation
f the reverse transcriptase at 95 ◦C for 5 min. qPCR analysis was
erformed using a Real-Time PCR System (Applied Biosystems)
ith a speciﬁc set of primers for each gene (VBC Genomics). The
orward and reverse primers used for gene expression were the
ollowing:ve stress in cardiac myocytes. Cardiac myocytes were either left untreated (control)
as  added for 10 min  before stimulation with H2O2. When the PPAR/ antagonist
0742.








Each reaction mix  contained 5 l KAPA SYBR FAST qPCR Kit
(Kapa Biosystems), 0.3 l oligonucleotides (10 pmol each of for-
ward and reverse primers) and 2 l cDNA (diluted 1:10). qPCR
analysis of -actin was performed as an endogenous control. PCR
conditions were 95 ◦C for 20 min, followed by 40 cycles of 95 ◦C
for 3 s and 60 ◦C for 30 min. Following qPCR, dissociation curve
analysis was  routinely performed to check for aberrant ampliﬁca-
tion products (e.g. primers-dimers). Relative changes in expression
were calculated using the 2(−ct) method.
2.8. Preparation of whole cell extracts
Cardiac myocytes were lysed at 4 ◦C in a buffer containing
20 mM -glycerophosphate, 20 mM HEPES pH 7.5, 50 mM NaF,
2 mM EDTA, 0.2 mM Na3VO4, 10 mM benzamidine, 5 mM DTT,
0.3 mM PMSF, 0.2 mM leupeptin, 0.01 mM  E64 and 1% (v/v) Tri-
ton X-100. Lysates were incubated on ice for 10 min  and then
centrifuged at 4 ◦C, for 15 min  at 10,000 × g. Supernatants were col-
lected, and total protein was measured using the Bradford assay
(BioRad, Hercules, CA, USA).2.9. Immunoblotting
Total protein extracts were boiled with 0.33 vol of SDS-
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3% glycerol (v/v), 300 mM Tris–HCl, pH 6.8, 130 mM dithiothre-
tol and 0.2% bromophenol blue (w/v). Proteins were separated by
DS-PAGE on 10% acrylamide, 0.275% (w/v) bis-acrylamide slab gels
nd transferred electrophoretically onto nitrocellulose membranes
0.45 m).  Nonspeciﬁc binding sites were blocked (30 min  at room
emperature) with 5% (w/v) nonfat milk powder in TBST buffer
20 mM Tris–HCl pH 7.5, 137 mM NaCl, 0.1% (v/v) Tween 20]. Mem-
ranes were incubated (overnight, 4 ◦C) with primary antibodies
iluted in TBST buffer containing 5% (w/v) bovine serum albumin,
hen washed in TBST buffer (3 × 5 min, room temperature). Primary
ntibodies against Bcl-2 (#2876), cleaved caspase-3 (#8698), PARP
#9542), -actin (#8457), -tubulin (#2125) (Cell Signaling, Bev-
rly, MA,  USA) and Bax (sc-7480, Santa Cruz Biotechnology, Texas,
SA) were used at various dilutions. Membranes were incubated
60 min, room temperature) with horseradish peroxidase (HRP)
onjugated secondary antibodies (1/5000) in TBST buffer contain-
ng 1% (w/v) non-fat milk powder, and they were then washed in
BST buffer (3 × 5 min, room temperature). Proteins were detected
y enhanced chemiluminescence (Cell Signaling, Beverly, MA,  USA)
nd quantiﬁed by scanning densitometry.
.10. Statistical analysis
Data are presented as mean ± SEM of n independent exper-
ments using different cell isolations from different animals.
tatistical analyses (ANOVA with Dunnett’s comparison test) were
erformed with signiﬁcance taken as being established at p < 0.05.
. Results
.1. Activation of PPARˇ/ı with the agonist GW0742 increases
ell viability and attenuates LDH release during exposure of
ardiac myocytes to H2O2
We  have previously shown that H2O2, at concentrations higher
han 0.05 mM,  decreases viability and induces apoptosis in cardiac
yocytes [24–26]. Consistent with these studies, exposure of car-
iac myocytes to 0.1 mM H2O2 for 3 h decreased the viability of
ardiac myocytes by almost 40% and caused an almost fourfold
ncrease in LDH activity measured in the culture medium (Fig. 2A
nd B). Pre-treatment of cardiac myocytes with the PPAR/ ago-
ist, GW0742, signiﬁcantly enhanced survival while attenuated
DH release. In order to determine whether this is a PPAR/-
ediated effect, the speciﬁc antagonist of PPAR/, GSK0660, was
sed. As shown in Fig. 2A, the PPAR/ agonist GW0742 was
nable to increase cell viability in the presence of the PPAR/
ig. 2. Effect of pre-treatment of cardiac myocytes with PPAR/ agonist GW0742 on viab
hey  were pretreated with PPAR/ agonist GW0742 (GW, 50 nM) and/or PPAR/ antagon
2O2 (0.1 mM)  for 3 h. (A) Cell viability was  measured using the MTT  method. (B) LDH act
f  4–5 independent experiments. *p < 0.05 compared with control, #p < 0.05 compared w
W0742.search 95–96 (2015) 102–110 105
antagonist GSK0660 indicating that this effect on cardiac myocyte
survival is dependent of PPAR/ activation. Similarly, the antag-
onist abolished the protective effect of PPAR/ agonist on LDH
release (Fig. 2B). Neither the agonist GW0742 nor the antagonist
GSK0660 had any effect on cell survival or LDH activity when used
alone.
3.2. Activation of PPARˇ/ı with the agonist GW0742 protects
cardiac myocytes from H2O2-induced apoptosis
Consistent with previous data [24–26] exposure of cardiac
myocytes to 0.1 mM  of H2O2 resulted in almost 50% increase in
the rate of apoptosis (Fig. 3A) whereas pre-treatment with the
PPAR/ agonist, GW0742, signiﬁcantly attenuated apoptosis. In
the presence of the PPAR/ antagonist GSK0660, the PPAR/  ago-
nist GW0742 was  unable to attenuate cardiac myocyte apoptosis
indicating that the protective effect of the agonist is dependent on
PPAR/ activation. To corroborate further these results, caspase-
3 activation and poly ADP-ribose polymerase (PARP) cleavage
were also evaluated under the same conditions. The activation
of caspase-3, the primary executioner of cell death by proteo-
lytic processing of pro-caspase, serves as an early marker of
apoptosis in various cell types. The activation of caspases results
in proteolytic cleavage of numerous substrates including PARP,
a nuclear enzyme involved in DNA repair that is considered
to be a hallmark of apoptosis [27]. As shown in Fig. 3B and
C, pre-treatment of cardiac myocytes with the PPAR/ agonist
GW0742 inhibited H2O2-induced caspase-3 and PARP cleavage, an
effect that is reversed in the presence of the PPAR/ antagonist
GSK0660.
3.3. Activation of PPARˇ/ı with the agonist GW0742 protects
cardiac myocytes from H2O2-induced oxidative stress
Given the protective effect of PPAR/ activation on car-
diac myocyte viability, and apoptosis, we sought to examine the
potential of PPAR/ agonist GW0742 to ameliorate intracellu-
lar generation of RONS in cardiac myocytes. Cells were loaded
with the ﬂuorophore CM-H2DCFDA before treatment with H2O2,
and/or PPAR/ agonist GW0742 and ﬂuorescence was determined
with ﬂow cytometry. As expected, exposure of cardiac myocytes
to H2O2 resulted in increased generation of RONS indicative of
oxidative stress (Fig. 4). However, addition of the PPAR/ agonist
completely abolished the increase of RONS induced by H2O2. The
inhibitory effect of PPAR/ agonist GW0742 on intracellular RONS
production was  reversed when the antagonist GSK0660 was added,
ility and H2O2-induced LDH release . Cardiac myocytes were either left untreated or
ist GSK0660 (GSK, 0.5 M).  Then they were incubated in the absence or presence of
ivity was  evaluated by spectrophotometric measurement. Results are mean ± SEM
ith H2O2, ˆp < 0.05 compared with cells treated with H2O2 and PPAR/ agonist
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Fig. 3. Effect of pre-treatment of cardiac myocytes with PPAR/ agonist GW0742 on H2O2-induced apoptosis levels and cleaved caspase-3 and PARP. Cardiac myocytes were
either  left untreated or they were pretreated with PPAR/ agonist GW0742 (GW, 50 nM)  and/or PPAR/ antagonist GSK0660 (GSK, 0.5 M). Then they were incubated in
the  absence or presence of H2O2 (0.1 mM)  for 3 h. (A) For the evaluation of apoptosis, cells were loaded with annexin/PI and ﬂuorescence was determined by ﬂow cytometry.
( ding w










rB,  C) Cell extracts were immunoblotted for cleaved caspase-3 and PARP. Equal loa
C)  Blots were quantiﬁed using scanning densitometry and plotted. Results are me
ontrol, #p < 0.05 compared with cells treated only with H2O2, ˆp < 0.05 compared w
erifying that this effect is mediated through PPAR/ activation.
urthermore, the mRNA levels of catalase, which is known to be
 PPAR/ target gene [28], were also measured under the same
onditions (Fig. 5). Catalase was up-regulated in cardiac myocytes
hat were pre-treated with PPAR/ agonist GW0742 as compared
ith the non-treated cells whereas addition of the PPAR/ antag-
nist abolished this effect indicating the activation of the receptor.
aken together these experiments point toward the antioxidant
ole of PPAR/ activation.as veriﬁed by immunoblotting for -tubulin. (B) Representative blots are shown.
EM of 3 experiments with independent cell preparations. *p < 0.05 compared with
lls treated with H2O2 and PPAR/ agonist GW0742.
3.4. PPARˇ/ı activation modulates Bcl-2 family protein
expression during cardiac myocyte oxidative stress
We  next determined whether the protective effect of PPAR/
activation can be attributable to upregulation of Bcl-2 protein. The
Bcl-2 family proteins are key components of the apoptotic pro-
cess in cardiac myocytes and the ratio Bcl-2/Bax is widely used
as a marker of apoptosis [24,25]. We,  thus, determined the pro-
tein levels of the anti-apoptotic Bcl-2 and the pro-apoptotic Bax.
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Fig. 4. Effect of pre-treatment of cardiac myocytes with PPAR/ agonist GW0742 on RONS generation. Cardiac myocytes were pre-loaded with 5-(and-6)-chloromethyl-
2′ ,7′-dichlorodihydroﬂuorescein diacetate (CM-H2DCFDA) and then they were either left untreated or they were pretreated with PPAR/ agonist GW0742 (GW, 50 nM)
and/or PPAR/ antagonist GSK0660 (GSK, 0.5 M).  Then they were incubated in the a
determined by ﬂow cytometry. Results are mean ± SEM of 5 independent experiments.
ˆp < 0.05 compared with cells treated with H2O2 and PPAR/ agonist GW0742.
Fig. 5. Effect of pre-treatment of cardiac myocytes with PPAR/ agonist GW0742
on  catalase mRNA expression. Cardiac myocytes were either left untreated or they
were pretreated with PPAR/ GW0742 (GW, 50 nM)  and/or PPAR/ antagonist
GSK0660 (GSK, 0.5 M).  Then they were incubated in the absence or presence of
H2O2 (0.1 mM)  for 3 h. Catalase mRNA levels were determined by real-time RT-PCR

















pre mean ± SEM of 5 independent experiments. *p < 0.05 compared with control,
p < 0.05 compared with treatment with H2O2, ˆp < 0.05 compared with cells treated
ith H2O2 and PPAR/ agonist GW0742.
s shown in Fig. 6, treatment of cardiac myocytes with PPAR/
gonist followed by H2O2 resulted in increased expression levels
f anti-apoptotic Bcl-2 compared with cells that were exposed to
2O2 alone. In a similar fashion, the H2O2-induced increase in Bax
as attenuated by the PPAR/ agonist. The effect of the agonist
W0742 on the expression of Bcl-2 family proteins was reversed
n the presence of the antagonist GSK0660, indicating that this is
 PPAR/-mediated effect. Taken together these results suggest
hat activation of PPAR/ leads to increased resistance to H2O2-
nduced cardiac myocyte apoptosis through upregulation of Bcl-2
nd concomitant downregulation of Bax.
.5. PPARˇ/ı activation leads to inhibition of MMP-2 and MMP-9
RNA expression in cardiac myocytes exposed to H2O2
Several studies have documented the role of matrix metallo-
roteinases (MMPs) in cardiac remodeling and the developmentbsence or presence of H2O2 (0.1 mM)  for 3 h. Changes in DCF ﬂuorescence were
 *p < 0.05 compared with control, #p < 0.05 compared with treatment with H2O2,
of cardiac disease [29]. Furthermore, recent evidence implicates
MMPs  in the proteolytic regulation of several intracellular proteins
in myocardial oxidative stress injury leading to cardiac dysfunc-
tion and cell death [30]. Thus, we  determined the effect of PPAR/
activation on MMP-2 and MMP-9 mRNA expression. As expected,
exposure of cardiac myocytes to H2O2 resulted in increased mRNA
expression of both MMP-2 and MMP-9 (Fig. 7A and B). Pre-
treatment of cardiac myocytes with PPAR/ agonist GW0742
resulted in attenuation of MMP-2 and MMP-9 mRNA levels (Fig. 7A
and B). This effect was  reversed by the addition of PPAR/ antag-
onist.
4. Discussion
In this study, we  focus on the potential beneﬁcial role of PPAR/
against oxidative stress induced dysfunction in cardiac myocytes.
We provide evidence that PPAR/ activation by its speciﬁc agonist
GW0742 protects cardiac myocytes from apoptosis via suppression
of RONS generation and MMP  gene expression.
The role of PPARs in the pathogenesis of various cardiovascular
diseases has not been fully elucidated and remains a matter of con-
troversy. Although PPAR/ is the less studied isoform, especially
in the heart, there is mounting evidence supporting its cardiopro-
tective role. PPAR/ is downregulated in rat heart after I/R [14]
whereas conditional cardiac-speciﬁc deletion of PPAR/ results
in increased cardiac lipid accumulation and cardiomyopathy [20].
Furthermore, PPAR/ agonists are cardioprotective in the set-
ting of I/R as manifested by a reduced infarct size and improved
postischaemic recovery of contractile function in different animal
models [31,32, Lazou et al. unpublished data]. In addition, activa-
tion of PPAR/ has been related to inhibition of hypertrophy and
inﬂammation through the suppression of NF-B and inﬂammatory
cytokines [33–35].
H2O2, as a physiologically relevant form of oxidative stress,
induces cardiac myocyte apoptosis [24–26]. In line with a
cardioprotective role of PPAR/, we demonstrate that pretreat-
ment of cardiac myocytes with the PPAR/ selective agonist
GW0742 increases cell viability and inhibits H2O2-induced apo-
ptosis (Figs. 2 and 3) Furthermore, pretreatment with the selective
108 E. Barlaka et al. / Pharmacological Research 95–96 (2015) 102–110
Fig. 6. PPAR/ activation modulates Bcl-2 family protein expression during oxidative stress. Cardiac myocytes were either left untreated or they were pretreated with
PPAR/  agonist GW0742 (GW, 50 nM)  and/or antagonist GSK0660 (GSK, 0.5 M). Then they were incubated in the absence or presence of H2O2 (0.1 mM)  for 3 h. Cell extracts
were  immunoblotted for Bcl-2 and Bax. Equal loading was  veriﬁed by immunoblotting for -actin. Representative blots are shown (upper panels). Blots were quantiﬁed


















csing  scanning densitometry and plotted (lower panels). Results are mean ± SEM o
p < 0.05 compared with cells treated only with H2O2, ˆp < 0.05 compared with cells
PAR/ antagonist GSK0660 abolishes the protection afforded
y GW0742, and this ﬁnding implies that the observed beneﬁcial
ffects of GW0742 are indeed secondary to the selective activation
f the PPAR/ receptor. There are several potential mechanisms
y which the PPAR/ agonist may  exert its anti-apoptotic effect.
ur results show that addition of the PPAR/ agonist in car-
iac myocytes ameliorates oxidative stress as evidenced by the
nhibition of RONS generation (Fig. 4). Many important endoge-
ous anti-oxidants such as Cu/Zn-superoxide dismutase (SOD1),
anganese superoxide dismutases (SOD2) and catalase contain
unctional PPAR response elements (PPREs) in their promoter and a
ig. 7. PPAR/ activation inhibits MMP-2 and MMP-9 gene expression. Cardiac myocytes
GW,  50 nM)  and/or the antagonist GSK0660 (GSK, 0.5 M)  for 10 min. Then they were in
xtracted and MMP-2 and MMP-9 were determined by real-time RT-PCR. Levels of mRN
re  mean ± SEM of 4–5 experiments with independent cell preparations. *p < 0.05 comp
ompared with cells treated with H2O2 and PPAR/ agonist GW0742.experiments with independent cell preparations. *p < 0.05 compared with control,
ed with H2O2 and PPAR/ agonist GW0742.
role of PPAR/ in the transcriptional regulation of these enzymes
has been previously reported [21,28,36]. Upregulation of the cata-
lase gene was observed in the presence of PPAR/ agonist in
cardiac myocytes (Fig. 5). Although catalase activity was not mea-
sured in this study, increased catalase gene expression may indicate
an increased anti-oxidant capacity. PPAR/ has been suggested to
inhibit ROS generation through the inhibition of NADPH oxidases in
vascular smooth muscle cells exposed to angiotensin II [37]. How-
ever, as the H2O2-induced RONS generation in cardiac myocytes
cannot be fully recovered in the presence of both PPAR/ ago-
nist and antagonist (Fig. 4), we  cannot exclude the possibility that
 were either left untreated or they were pre-treated with PPAR/ agonist GW0742
cubated in the absence or presence of H2O2 (0.1 mM)  for 3 h. (A, B) Total RNA was
A were normalized to the mRNA levels of the housekeeping gene -actin. Results
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he agonist GW0742 has an additional anti-oxidant effect indepen-
ent of PPAR/ activation. In fact, we have previously shown that
PAR/ agonist GW0742 can inhibit the phenylephrine-induced
ONS generation in cardiac myocytes through a non-genomic
edox mechanism [38].
Bcl-2 family proteins are key components of the apoptotic
rocess in cardiac myocytes [5]. Bcl-2 proteins can be regulated
ither by transcription, heterodimerization or proteolytic cleav-
ge, whereas their phosphorylation status plays important role in
hose events. Treatment with PPAR/ agonist GW0742 reversed
he detrimental effect of H2O2 on Bcl-2 expression while it led to a
igniﬁcant decrease of the proapoptotic Bax protein levels (Fig. 6).
hese results are consistent with previous studies demonstrat-
ng cardioprotection associated with modulation of cardiac levels
f antiapoptotic (Bcl-2 and Bcl-xl) or proapoptotic (Bax and Bad)
roteins [17,31,39]. The present data do not document a direct
ausal link between PPAR/ activation and modulation of Bcl-2
r Bax expression. It is possible that the observed Bcl-2 upregula-
ion in our experimental setting results from the PPAR/-induced
melioration of oxidative stress or PPAR/ crosstalk with other
ignaling pathways. Furthermore, we cannot exclude the possi-
ility that besides Bcl-2 and Bax, other proteins acting in the
itochondrial-dependent apoptotic pathway are also affected by
PAR/ activation and might contribute to the observed cardio-
rotective effects.
Increased RONS promote MMP  activities. MMP  activation is
ssociated with degradation and remodeling of extracellular matrix
nder pathological conditions, thus leading to heart failure [40].
t is now becoming clear that, beyond their effects on matrix
etabolism, MMPs  (in particular MMP-2) are capable of modulat-
ng inﬂammatory pathways by processing cytokines, chemokines,
nd growth factors [41] as well as affecting many other rele-
ant mediators involved in a variety of functions and pathogenic
echanisms leading to cardiac dysfunction [30,42]. In fact, MMP-
 has been shown to be involved in the intracellular degradation
f troponin I [43], myosin light chain 1 [44] and nuclear PARP
45,46]. Inhibition of MMP  activity has been shown to protect
he myocardium form oxidative/nitrosative stress-induced injury
uggesting novel targets for cardiac failure management [10,47].
he data of this study clearly demonstrate that PPAR/ agonist
W0742 downregulates the H2O2-induced MMP-2 and MMP-9
ene overexpression (Fig. 7) in cardiac myocytes. Moreover this
ffect is reversed by administration of the PPAR/ antagonist
SK0660. It is not clear whether there is a direct link between PPAR
ctivation and MMP  inhibition. The inhibitory effect of PPARs on
F-B is well documented [19], whereas there are reports demon-
trating a role of NF-B in the activation of MMPs  [48,49]. Thus,
he observed MMP  dowregulation in cardiac myocytes (Fig. 7)
ay  be the result of the anti-inﬂammatory action of PPAR/. In
his context, it has been shown that a PPAR/ agonist markedly
uppresses the IL-1-induced MMP-2 and MMP-9 expression in
ascular smooth muscle cells [50]. This issue warrants further
nvestigation. Furthermore, we cannot rule out the possibility that
MP  suppression by the agonist GW0742 in our experimental
odel might be a secondary effect through the modulation of
xidative stress.
In conclusion, our results demonstrate that the PPAR/ ago-
ist GW0742 inhibits cardiac myocyte injury by reducing oxidative
tress and inhibiting MMP  expression and apoptosis. Its protec-
ive effects are dependent on the activation of PPAR/ because
hey are abolished by pretreatment with the PPAR/ antagonist
SK0660. Although additional experiments are needed to clarify
he role of PPAR/ in cardiac myocytes apoptosis, the results pre-
ented here suggest that the connection between PPAR signaling
nd MMP  suppression might represent a new target for the man-
gement of oxidative stress-induced cardiac dysfunction.
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